Navigation Links
Gevo Doesn't Infringe Butamax's '017 Patent; Gevo was First to Invent Enzyme in '017 Patent; Gevo has Advanced Beyond That and Now Uses Different Enzymes
Date:8/8/2012

ENGLEWOOD, Colo., Aug. 8, 2012 /PRNewswire/ -- Gevo, Inc. (NASDAQ: GEVO), a leading renewable chemicals and next-generation biofuels company, said today that the latest lawsuit filed by Butamax™ Advanced Biofuels LLC (Butamax) alleging infringement by Gevo of Butamax's U.S. Patent No. 8,222,017 ('017 Patent), like the last one filed by Butamax against Gevo, will be shown to have no merit.  Gevo said it is also challenging the validity of Butamax's '017 Patent.

"We don't infringe the enzyme claimed in Butamax's patent," said Brett Lund, Executive Vice President and General Counsel of Gevo. "Gevo previously developed and patented a modified E. coli KARI enzyme, and since then, our technology has advanced well beyond this. Our industry-leading process now utilizes an enzyme that is not derived from, or in any way related, to the E. coli KARI enzyme described in the newly issued patent. We provided proof of our non-infringement to Butamax and they still sued us." 

"We also challenge the validity of the just-issued Butamax patent. We strongly believe that Gevo was the first to invent the claimed subject matter," Lund said. "Therefore, we have filed a 'Request for Interference' (Serial No. 13/271,084) with the U.S. Patent and Trademark Office to demonstrate that the technology is, in fact, a Gevo invention. Gevo's technology represents the industry standard for the optimization of the native yeast isobutanol pathway. Our commitment to innovation is what sustains this leadership position. We see this unfounded lawsuit as another attempt by Butamax to stall our significant advances in the commercialization of renewable isobutanol."

"This lawsuit is part and parcel of an ongoing effort by Butamax and its corporate parents, DuPont and British Petroleum, to divert attention from the well-established fact that much of Butamax's technology
'/>"/>

SOURCE Gevo, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Butamax™ Responds to Gevo Patent Infringement Lawsuit
2. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
3. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
4. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
5. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
6. Webcor Builders Selected as the General Contractor for First Phase of LA BioMeds New Campus Master Plan
7. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
8. Tiger Woods Gives Exclusive First Interview Since POWERED by FUSE Announcement!
9. The Pharmabiotic Research Institute (PRI) is Preparing to Publish its First Works on the Therapeutic and Medicinal Potential of Probiotics
10. Eye Surgery Center of Michigan First in Southeast Michigan to Perform Bladeless Cataract Surgery Using New LenSx® Laser Technology
11. Amgen Announces 2012 First Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... June 29, 2015  Neuralstem, Inc. (NYSE MKT: CUR), ... develop small molecule and cell therapy treatments for central ... approved for listing on the NASDAQ Capital Market under ... to trade on the NYSE MKT until the market ... Capital Market is expected to commence on July 13, ...
(Date:6/29/2015)... June 29, 2015   Veracyte, Inc . (Nasdaq: ... field of molecular cytology, today announced that it has ... Top Workplaces list for the second year in a ... solely on an annual survey of Bay Area-company employees. ... the degree to which Veracyte values our employees and ...
(Date:6/26/2015)... Mass. , June 26, 2015  SeraCare ... vitro diagnostics manufacturers, today announced that it has ... with the National Cancer Institute (NCI), part of ... materials and positive controls for cancer assays.  The ... mix and accurately quantitate control DNA biosynthetics spiked ...
(Date:6/26/2015)... (PRWEB) , ... June 26, 2015 , ... ... Department of Agriculture (USDA), Grain Inspection, Packers and Stockyards Administration (GIPSA) awarded a ... as vomitoxin in feed and grains utilizing Charm’s ROSA DONQ-FAST5 Test. This 5 ...
Breaking Biology Technology:Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2
... www.tedmed.com , the world,s leading multi-disciplinary conference on the future ... of the conference will take place in Washington, DC at ... April 11-13, 2012. From 2009 to 2011, San ... and technology developers. The move to the Nation,s Capital and ...
... -- Andrew Barron, Rice University,s Charles W. Duncan, Jr. ... science, is the winner of the prestigious 2011 World ... the World Technology Summit and Awards gala at the ... the application of nanotechnology to fundamental problems in energy ...
... VetNostic Laboratories® offers state-of-the-art genetic testing services for ... are able to accurately and specifically determine whether ... reliable identification of these "carriers" ensures healthy litters ... VetNostic Laboratories® is pleased to introduce two new ...
Cached Biology Technology:TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 2TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 3TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 4TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 5Rice's Barron wins World Technology Award for Materials 2VetNostic Laboratories® Announces New Testing for Dog Breeds 2VetNostic Laboratories® Announces New Testing for Dog Breeds 3
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - ... partnership centralized around the incorporation of handyem,s HPC-150 ... diagnostic laboratory, the Mo-POD™. This unprecedented model of ... International Conference at the Pennsylvania ... from June 15 th to 18 th ...
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue guidance for ... at least 340 MSEK to that it will amount to ... growth and orders received the revenue guidance for 2015 is ... will exceed 1,500 MSEK to an updated guidance that revenue ... Due to receipt of orders of touch fingerprint sensors with ...
(Date:6/15/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... market, announces that its leading payment security technology, the Wocket® ... @ NYC June 18th. Digital Experience! @ NYC ... technology to over 300 of the top media covering the ... in New York City from 6:00 ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... cells become after being exposed to a specialized electrical ... cancerous or a stage of cancer already invading other ... the electrical process and found cells that expanded the ... disease has spread beyond its point of origin. The ...
... power to constrict blood vessels and help patients manage ... more about how endothelin functions naturally and in disease ... Despite strong laboratory evidence that blocking endothelin-1 receptors would ... health problems, the drugs failed patients, says Dr. Adviye ...
... Within the last few years the number of ... increased considerably. A worthwhile effort as, after all, it concerns ... of transport checks are offered by terahertz radiation. Before this ... to be measured quantitatively, so that damage to health caused ...
Cached Biology News:Expanding cell girth indicates seriousness of breast cancer 2Better understanding of blood vessel constrictor needed to harness its power for patients 2Checking people at airports -- with terahertz radiation 2
... containing an overproducing clone of M-MLV Reverse ... the polymerization of DNA using template DNA, ... large mRNAs, >10 kb, may be synthesized. ... RNase H activity than AMV Reverse Transcriptase ...
... catalyzes the template-directed polymerization of nucleotides into ... Polymerase I possesses a 3?5 exonuclease activity ... rate during DNA replication, and also contains ... enzyme to replace nucleotides in the growing ...
Request Info...
... yeast/leuconostoc overproducer ATP: D-hexose 6- ... One unit of HK will ... in 1 min at 25C ... of G6P-DH will oxidize 1 ...
Biology Products: